Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Ovid therapeutics Inc (OVID)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.58-5.84%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for OVID yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
maintain sufficient capital to fund operations | A supporting condition in Ovid therapeutics Inc's published investment case. The stated target is no need for dilutive capital raises beyond current runway in next 12 months. | Intact | announces dilutive capital raise within next 12 months | Runway extended to 2029 vs 12-month target Ovid cashed in a bet to fund operations into 2029, reinforcing financial runway and capital sufficiency. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage biotech, where the case depends on advancing drug candidates rather than established earnings. The long-term thesis is on watch: management is meeting key development and funding milestones, but recent financial performance remains weak and risk is elevated.
The valuation model points to a 2.14-times premium versus peers and an expectations gap of 0.32, though confidence in those estimates is low. The priced-in signal is tagged unjustified, with no fragility gates triggered; the evidence does not show precisely which expectations the market assumes.
Near term, OVID remains loss-making, and its recent financial performance sits well below its industry cohort; the latest event list also includes an earnings beat. Over the multi-year view, OV4071 has advanced on schedule, OV329 studies are progressing with further studies planned, and cash and marketable securities rose to support operations into 2029. The next results remain a risk, given the industry's high miss rate and recent peer misses.
The thesis depends on clinical progress, especially the planned OV4071 ketamine challenge study and continued OV329 development across seizure disorders. A guidance cut would be a meaningful negative, while continued strong results and guidance from healthcare peers could support sector momentum; weakening employment data could add pressure to cyclical and healthcare names.
Over the next 1 to 3 years, OVID's case rests on converting clinical milestones and a longer funding runway into stronger business progress, while execution and sector risks remain elevated. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
reduce losses and improve EPS |
| A primary condition in Ovid therapeutics Inc's published investment case. The stated target is EPS loss narrows by at least 10% in FY27 vs FY26. |
| Improving |
| EPS loss does not improve or worsens in FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
successful clinical development and regulatory milestones | A primary condition in Ovid therapeutics Inc's published investment case. The stated target is achieve key clinical milestones for OV329 and OV4071 in next 12 months. | Intact | failure to meet clinical or regulatory milestones in next 12 months | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
revenue stabilizes or grows beyond 2026 | A primary condition in Ovid therapeutics Inc's published investment case. The stated target is revenue growth >= 0% YoY in FY27. | Improving | revenue growth falls below 0% in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.53 → $-0.39 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.53 | $187,500 | 7 / 7 |
| 2026-07-25 | $-0.53 | $187,500 | 7 / 7 |
| 2026-07-26 | $-0.53 | $187,500 | 7 / 7 |
| 2026-07-27 | $-0.53 | $187,500 | 7 / 7 |
| 2026-07-28 | $-0.53 | $187,500 | 7 / 7 |
| 2026-07-29 | $-0.53 | $187,500 | 7 / 7 |
| 2026-07-30 | $-0.45 | $166,670 | 6 / 9 |
| 2026-07-31 | $-0.53 | $187,500 | 7 / 7 |
| 2026-08-01 | $-0.53 | $187,500 | 7 / 7 |
| 2026-08-02 | $-0.45 | $166,670 | 6 / 9 |
| 2026-08-03 | $-0.45 | $166,670 | 6 / 9 |
| 2026-08-04 | $-0.45 | $166,670 | 6 / 9 |
| 2026-08-05 | $-0.44 | $166,670 | 6 / 9 |
| 2026-08-06 | $-0.44 | $166,670 | 6 / 9 |
| 2026-08-07 | $-0.52 | $187,500 | 7 / 7 |
| 2026-08-08 | $-0.44 | $166,670 | 6 / 9 |
| 2026-08-09 | $-0.44 | $166,670 | 6 / 9 |
| 2026-08-10 | $-0.44 | $166,670 | 6 / 9 |
| 2026-08-12 | $-0.44 | $166,670 | 6 / 9 |
| 2026-08-13 | $-0.52 | $187,500 | 7 / 7 |
| 2026-08-14 | $-0.52 | $187,500 | 7 / 7 |
| 2026-08-15 | $-0.52 | $187,500 | 7 / 7 |
| 2026-08-16 | $-0.52 | $187,500 | 7 / 7 |
| 2026-08-17 | $-0.52 | $187,500 | 7 / 7 |
| 2026-08-18 | $-0.52 | $187,500 | 7 / 7 |
| 2026-08-19 | $-0.52 | $187,500 | 7 / 7 |
| 2026-08-20 | $-0.41 | $279,125 | 8 / 7 |
| 2026-08-21 | $-0.41 | $319,000 | 8 / 7 |
| 2026-08-22 | $-0.41 | $372,167 | 8 / 7 |
| 2026-08-23 | $-0.41 | $372,167 | 8 / 7 |
| 2026-08-24 | $-0.41 | $372,167 | 8 / 7 |
| 2026-08-25 | $-0.41 | $372,167 | 8 / 7 |
| 2026-08-26 | $-0.41 | $372,167 | 8 / 7 |
| 2026-08-27 | $-0.41 | $372,167 | 8 / 7 |
| 2026-08-28 | $-0.41 | $372,167 | 8 / 7 |
| 2026-08-29 | $-0.41 | $372,167 | 8 / 7 |
| 2026-08-30 | $-0.41 | $372,167 | 8 / 7 |
| 2026-08-31 | $-0.41 | $372,167 | 8 / 7 |
| 2026-09-01 | $-0.41 | $372,167 | 8 / 7 |
| 2026-09-02 | $-0.41 | $372,167 | 8 / 7 |
| 2026-09-03 | $-0.41 | $366,600 | 8 / 7 |
| 2026-09-04 | $-0.41 | $366,600 | 8 / 7 |
| 2026-09-05 | $-0.42 | $305,500 | 8 / 7 |
| 2026-09-06 | $-0.42 | $305,500 | 8 / 7 |
| 2026-09-07 | $-0.42 | $305,500 | 8 / 7 |
| 2026-09-08 | $-0.42 | $305,500 | 8 / 7 |
| 2026-09-09 | $-0.42 | $305,500 | 8 / 7 |
| 2026-09-10 | $-0.42 | $305,500 | 8 / 7 |
| 2026-09-11 | $-0.42 | $305,500 | 8 / 7 |
| 2026-09-12 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-13 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-14 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-15 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-16 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-17 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-18 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-19 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-20 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-21 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-22 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-23 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-24 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-25 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-26 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-27 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-28 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-29 | $-0.41 | $319,000 | 8 / 7 |
| 2026-09-30 | $-0.41 | $319,000 | 8 / 7 |
| 2026-10-01 | $-0.41 | $319,000 | 8 / 7 |
| 2026-10-02 | $-0.41 | $319,000 | 8 / 7 |
| 2026-10-03 | $-0.41 | $319,000 | 8 / 7 |
| 2026-10-04 | $-0.41 | $319,000 | 8 / 7 |
| 2026-10-05 | $-0.41 | $319,000 | 8 / 7 |
| 2026-10-06 | $-0.40 | $319,000 | 8 / 7 |
| 2026-10-07 | $-0.40 | $319,000 | 8 / 8 |
| 2026-10-08 | $-0.40 | $319,000 | 8 / 8 |
| 2026-10-09 | $-0.40 | $319,000 | 8 / 8 |
| 2026-10-10 | $-0.40 | $319,000 | 8 / 8 |
| 2026-10-11 | $-0.39 | $279,125 | 9 / 8 |
| 2026-10-12 | $-0.39 | $279,125 | 9 / 9 |
| 2026-10-13 | $-0.39 | $279,125 | 9 / 9 |
| 2026-10-14 | $-0.39 | $279,125 | 9 / 9 |
| 2026-10-15 | $-0.39 | $279,125 | 9 / 9 |
| 2026-10-16 | $-0.39 | $470,333 | 9 / 9 |
| 2026-10-17 | $-0.39 | $470,333 | 9 / 9 |
| 2026-10-18 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-19 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-20 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-21 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-22 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-23 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-24 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-25 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-26 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-27 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-28 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-29 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-30 | $-0.39 | $470,333 | 10 / 9 |
| 2026-10-31 | $-0.39 | $470,333 | 10 / 9 |
| 2026-11-01 | $-0.39 | $470,333 | 10 / 9 |
| 2026-11-02 | $-0.39 | $470,333 | 10 / 9 |
| 2026-11-03 | $-0.39 | $470,333 | 10 / 9 |
| 2026-11-04 | $-0.39 | $470,333 | 10 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.